menu
    • menu

    Company profile for Replimune

    NEW Drugs in Dev: 6
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Replimune has assembled a world-class team who together pioneered the development of the first FDA-approved oncolytic immunotherapy. Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, and generating a powerful patient-specific, systemic ...
    Replimune has assembled a world-class team who together pioneered the development of the first FDA-approved oncolytic immunotherapy. Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, and generating a powerful patient-specific, systemic anti-tumor immune response.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ReplimuneUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    18 Commerce Way Woburn MA 01801
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://replimune.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/replimune-inc
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/replimune?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Replimune Lays Off Over 200 In Massachusetts
    Replimune Lays Off Over 200 In Massachusetts

    22 Apr 2026

    // BIOSPACE

    https://www.biospace.com/biospace-layoff-tracker

    BIOSPACE
    22 Apr 2026
    Share Share
    Replimune Cuts Will Leave Over 200 Jobless In Massachusetts
    Replimune Cuts Will Leave Over 200 Jobless In Massachusetts

    21 Apr 2026

    // BIOSPACE

    https://www.biospace.com/job-trends/replimune-cuts-will-leave-over-200-jobless-in-massachusetts

    BIOSPACE
    21 Apr 2026
    Share Share
    Replimune's 'Challenging Path Forward' Will Include Job Cuts
    Replimune's 'Challenging Path Forward' Will Include Job Cuts

    14 Apr 2026

    // BIOSPACE

    https://www.biospace.com/biospace-layoff-tracker

    BIOSPACE
    14 Apr 2026
    Share Share
    Replimune's Drug for Advanced skin cancer fails to win FDA nod
    Replimune's Drug for Advanced skin cancer fails to win FDA nod

    11 Apr 2026

    // REUTERS

    https://www.reuters.com/legal/litigation/us-fda-declines-approve-replimunes-drug-advanced-skin-cancer-2026-04-10/

    REUTERS
    11 Apr 2026
    Share Share
    Biotech Eyes Replimune's RP1 as Key FDA Direction Indicator
    Biotech Eyes Replimune's RP1 as Key FDA Direction Indicator

    06 Apr 2026

    // BIOSPACE

    https://www.biospace.com/fda/biotech-looks-to-replimune-rp1-decision-as-first-indicator-of-fda-direction

    BIOSPACE
    06 Apr 2026
    Share Share
    Replimune To Present At Two Upcoming Investor Conferences
    Replimune To Present At Two Upcoming Investor Conferences

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247322/0/en/Replimune-to-Present-at-Two-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search